Summary
164.14 2.54(1.57%)10/15/2024
Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.49 | 2.82 | -1.73 | 9.99 | 11.27 | 5.03 | 38.55 | 254,393.47 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 164.14 | |
| Open | 160.00 | |
| High | 166.74 | |
| Low | 159.00 | |
| Volume | 8,502,958 | |
| Change | 2.41 | |
| Change % | 1.49 | |
| Avg Volume (20 Days) | 3,965,020 | |
| Volume/Avg Volume (20 Days) Ratio | 2.14 | |
| 52 Week Range | 143.13 - 168.85 | |
| Price vs 52 Week High | -2.79% | |
| Price vs 52 Week Low | 14.68% | |
| Range | 2.59 | |
| Gap Up/Down | -2.14 | |
Fundamentals | ||
| Market Capitalization (Mln) | 388,504 | |
| EBIDTA | 30,613,000,192 | |
| PE Ratio | 22.2749 | |
| PEG Ratio | 0.8879 | |
| WallStreet Target Price | 172.72 | |
| Book Value | 29.0940 | |
| Earnings Per Share | 6.7300 | |
| EPS Estimate Current Quarter | 2.6400 | |
| EPS Estimate Next Quarter | 2.7300 | |
| EPS Estimate Current Year | 10.6500 | |
| EPS Estimate Next Year | 10.9500 | |
| Diluted EPS (TTM) | 6.7300 | |
| Revenues | ||
| Profit Marging | 0.4492 | |
| Operating Marging (TTM) | 0.2951 | |
| Return on asset (TTM) | 0.0801 | |
| Return on equity (TTM) | 0.2424 | |
| Revenue TTM | 85,647,998,976 | |
| Revenue per share TTM | 34.4770 | |
| Quarterly Revenue Growth (YOY) | 0.0230 | |
| Quarterly Earnings Growth (YOY) | 0.1060 | |
| Gross Profit (TTM) | 63,954,000,000 | |
| Dividends | ||
| Dividend Share | 4.7600 | |
| Dividend Yield | 0.0331 | |
| Valuations | ||
| Trailing PE | 22.2749 | |
| Forward PE | 13.8504 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1690 | |
| Revenue Enterprise Value | 4.2497 | |
| EBITDA Enterprise Value | 15.5187 | |
| Shares | ||
| Shares Outstanding | 2,406,680,064 | |
| Shares Float | 2,401,841,758 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.09 | |
| Institutions (%) | 71.37 | |
10/15 15:45 EST - reuters.com
J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury finds
Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found on Tuesday.
J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury finds
Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found on Tuesday.
10/15 15:30 EST - youtube.com
3-Stock Lunch: UnitedHealth, Johnson & Johnson & Wolfspeed
Jay Hatfield, Infra-Cap CEO, joins 'Power Lunch' to discuss stock plays for three stocks.
3-Stock Lunch: UnitedHealth, Johnson & Johnson & Wolfspeed
Jay Hatfield, Infra-Cap CEO, joins 'Power Lunch' to discuss stock plays for three stocks.
10/15 14:20 EST - invezz.com
Are JNJ's mergers and acquisitions weighing down company's performance?
Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business performance was overshadowed by the recent acquisition of V-Wave, a cardiac device company.
Are JNJ's mergers and acquisitions weighing down company's performance?
Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business performance was overshadowed by the recent acquisition of V-Wave, a cardiac device company.
10/15 14:14 EST - benzinga.com
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
10/15 12:51 EST - proactiveinvestors.com
J&J beats Q3 earnings estimates, raises full-year sales guidance
Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per share (EPS) of $2.42 were down from $2.66 in the year-ago quarter but topped estimates of $2.22.
J&J beats Q3 earnings estimates, raises full-year sales guidance
Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per share (EPS) of $2.42 were down from $2.66 in the year-ago quarter but topped estimates of $2.22.
10/15 12:31 EST - seekingalpha.com
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Jayson Bedford - Raymond James Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Jayson Bedford - Raymond James Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
10/15 12:30 EST - zacks.com
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
10/15 11:54 EST - youtube.com
J&J CFO Wolk on Product Pipeline, Strategy and Talc Lawsuit
Johnson & Johnson CFO Joseph Wolk discusses the company's product pipeline, acquisition strategy and the latest on the talc baby powder lawsuit on "Bloomberg Open Interest." J&J reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine Darzalex.
J&J CFO Wolk on Product Pipeline, Strategy and Talc Lawsuit
Johnson & Johnson CFO Joseph Wolk discusses the company's product pipeline, acquisition strategy and the latest on the talc baby powder lawsuit on "Bloomberg Open Interest." J&J reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine Darzalex.
10/15 10:47 EST - youtube.com
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.
10/15 10:44 EST - schaeffersresearch.com
Blue Chip Faces Off With Resistance After Earnings
Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.
Blue Chip Faces Off With Resistance After Earnings
Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.
10/15 10:35 EST - investopedia.com
Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs
Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and acquisitions.
Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs
Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and acquisitions.
10/15 10:31 EST - zacks.com
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10/15 10:01 EST - seekingalpha.com
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enhances Johnson & Johnson's MedTech business, opening new opportunities in the high-growth heart failure device market. Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4% adjusted operational revenue growth.
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enhances Johnson & Johnson's MedTech business, opening new opportunities in the high-growth heart failure device market. Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4% adjusted operational revenue growth.
10/15 08:37 EST - youtube.com
J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, R&D investment, growth outlook, state of the company's talc settlement, and more.
J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, R&D investment, growth outlook, state of the company's talc settlement, and more.
10/15 08:35 EST - zacks.com
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago.
10/15 08:00 EST - prnewswire.com
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia gravis (gMG).
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia gravis (gMG).
10/15 07:18 EST - marketwatch.com
Johnson & Johnson stock rises on Q3 sales beat and guidance raise
Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance.
Johnson & Johnson stock rises on Q3 sales beat and guidance raise
Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance.
10/15 06:25 EST - businesswire.com
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcar.
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcar.
10/15 06:22 EST - reuters.com
J&J lifts profit and sales forecasts, beats Wall Street expectations
Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.
J&J lifts profit and sales forecasts, beats Wall Street expectations
Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.
10/15 06:20 EST - businesswire.com
Johnson & Johnson Reports Q3 2024 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson's strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced our pipeline with regulatory approvals for TREMFYA and RYBREVANT, submitted an IDE for our general surgery robotic.
Johnson & Johnson Reports Q3 2024 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson's strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced our pipeline with regulatory approvals for TREMFYA and RYBREVANT, submitted an IDE for our general surgery robotic.